VALIANTORGNSE26 May 2022

Valiant Organics Limited has informed the Exchange about Investor Presentation.

Valiant Organics Limited

••••

Valiant Organics Limited

Date: May 26,2022

To, Listing/Compliance Department BSE LTD Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001.

BSE CODE-540145

To, Listing/Compliance Department National Stock Exchange of India Limited "Exchange Plaza", Plot No. C/1, G Block Bandra-Kurla Complex, Sandra (E), Mumbai- 400 051. NSE CODE-VALIANTORG

Sub: Investor Presentation. Ref: Regulation 30(6) of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Please find attached herewith Q4 Financial Year 2021-2022 Results presentation of the Company for your records.

Kindly take the same on your record.

Thanking You,

Yours Faithfully, For Valiant Organics Limited

Regd. Office : 109, Udyog Kshetra, 1st Floor, Mulund Goregaon Link Rd, Mulund West, Mumbai 400 080, India. +91 22 6797 6683 • info@valiantorganics.com • www.valiantorganics.com CIN NO. : L24230MH2005PLC151348

E a r n i n g s P r e s e n t a t i o n | Q 4 - F Y 2 2 / F Y 2 2

SNAPSHOT

One of the largest chlorophenol derivatives manufacturer globally

One of the leading manufacturer of Benzene derivatives products

One of the largest domestic PNA manufacturer

One of the few commercial players in Ortho Anisidine and Para Anisidine

Amongst 1st few domestic PAP Manufacturers

Diversified client base across Pharmaceuticals, Dyes & Pigments, Agrochemicals and specialty chemicals.

6 Manufacturing units across 5 Locations

5 Zero Liquid Discharge plants

Total Production Capacity of 70,000 TPA

850+ Employees

Company Overview

Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India.

The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications.

Key chemistries include Chlorination, Hydrogenation, Ammonolysis, Acetylation, Sulphonation, Methoxylation amongst others.

Over the years the company has primarily focused on manufacturing specialty chemicals that have a high demand but low supply and are primarily dependent on imports.

The company is listed on both the BSE and NSE with a market capitalization of INR 24,982 Mn as on 31st March, 2022.

Operating Revenue (INR Mn) and EBITDA Margin (%)

FY22 Revenue Break-up – Chemistries

FY21 Revenue Break-up – End user Industry

14000

12000

10000

8000

6000

4000

2000

6,923

6,749

26.0%

26.7%

7,548

27.2%

11,533

17.8%

50.0%

45.0%

40.0%

35.0%

30.0%

25.0%

20.0%

15.0%

10.0%

5.0%

0.0%

FY19

FY20 Revenue

FY21 EBITDA Margin

FY22

Others, 9%

Ammonolysis, 31%

Chlorination, 29%

Hydrogenation, 31%

Dyes & Pigments, 20%

Pharmaceuticals, 10%

Specialty Chemicals, 30%

Agro Chemicals, 40%

Valiant Organics Limited | May 2022

Chemistries And Product Basket

Hydrogenation

Ortho Anisidine Para Anisidine IPPCA

Key Products: • • • • Meta Chloro Aniline • Para Amino Phenol • Ortho Amino Phenol

Industries Served: • • • •

Dyes Pigments Pharmaceutical Agro Chemicals

Others Acetylation Key Products: • • •

6 Acetyl OAPSA OA Acetanilide PA Acetanilide

Industries Served: • Dyes

Sulphonation Key Products: • OT5SA • 4B Acid • 2B Acid

Methoxylation Key Products: • •

Ortho Nitro Anisole Para Nitro Anisole

Industries Served: • Dyes • Pigments

31%

29%

Chlorination

Key Products: • • • • •

Para ChloroPhenol (PCP) Ortho ChloroPhenol (OCP) 2,4 Di Chlorophenol (2,4 DCP) 2,6 Di ChloroPhenol (2,6 DCP) 2,4,6 Tri ChloroPhenol (2,4,6 TCP)

Industries Served: • Agro Chemicals • Cosmetics • Veterinary • Pharmaceuticals

31%

Ammonolysis

Key Products: • •

Para Nitro Aniline Ortho Chloro Para Nitro Aniline

Industries Served: • •

Dyes Pigments

Valiant Organics Limited | May 2022

Manufacturing Footprint

CHLORINATION – SARIGAM • Capacity: 18,000 MTPA • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, 2,4,6 TCP

AMMONOLYSIS - VAPI • •

Capacity: 9,000 MTPA Products: PNA, OCPNA

AMMONOLYSIS - TARAPUR • Capacity: 6,600 MTPA • Products: PNA

HYDROGENATION & METHOXYLATION- JHAGADIA UNIT 1 • •

Capacity: 27,000 MTPA Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS

HYDROGENATION – JHAGADIA UNIT 2 • •

Capacity: 12,000 MTPA Products: PAP, PHARMA INTERMEDIATES

ACETYLATION & SULPHONATION – AHMEDABAD • •

Capacity: 1,800 MTPA Products: 6 ACETYL OAPSA, OA/PA ACETANILIDE, OT5SA

Valiant Organics Limited | May 2022

Key Strengths

Domain expertise and broad process understanding in a variety of chemistries. The executive team is made up of first-generation technocrats with more than 50 years of collective expertise.

Wide supply chain provides the continuous availability of adequate and high-quality raw materials and manufacturing.

Plant locations are strategically located near ports to provide a competitive advantage, significant logistical cost savings, and faster delivery times.

Robust Business Model

Integrated Operations

Strong Customer Relations

Distinct Product Portfolio

Domain Knowledge

Widespread Supply Chain

Strategic Location of Plants

Diverse product range and client base across numerous industries and countries provides a sustainable business model in multiple chemistries by lowering product, industry, and geographical risk.

Multi-use and backward integrated plants to produce a wide range of products and tailor them to meet the diverse needs, technical qualifications, batch sizes, and delivery schedules of our clients.

Established multi-year relationships with clients in both domestic and international markets due to high-quality standards, innovative production capabilities.

Manufacturing a diverse range of intermediates as well as value-added products for a variety of industries.

Valiant Organics Limited | May 2022

Capex Projects

Product

Commissioned

Para Nitro Aniline (PNA) & Ortho Chloro Para Nitro Aniline (OCPNA)

Ortho Nitro Anisole (ONA)

Para Nitro Anisole (PNA)

Para Anisidine (PA)

Ongoing Projects

Installed Capacity (MT per month)

Approx. Capex (INR Mn)

Project Status

Remarks

550

600

200

150

~ 70

Completing phase-wise

• Expansion from 550 TPM to 750 TPM at Vapi plant • Full capacity addition in progress

Completed in Q4 FY’20

• Backward integrated for existing product Ortho Anisidine

~ 350-400

Completed in Q4 FY’20

• Captive use towards manufacture of Para Anisidine

Completed in Q4 FY’20

• Currently mostly being imported in India • Valiant will be one of the major producers in India

Para Amino Phenol (PAP)

1,000

~ 2,200

Completed in Q4 FY’21

the actual production delayed

• Currently, limited availability domestically and mostly imported • Due to technical difficulties in achieving the desired specification,

Ortho Amino Phenol (OAP)

100

~ 120

Pharma Intermediates

~ 600

Phase 1 production to commence from Q2 FY’23

Expected production from Q2 FY’23

• Ramp up in process for batch operations on-going. • Simultaneous work on-going towards continuous process

• Currently, entirely imported in India • Part of the production will be utilized as forward integration for

one of company's existing products

• Trial run successful

• Multi-purpose plant for forward integration within Group

Company

• Will manufacture N-1, N-2 raw materials for API products • Delay due to approvals

Valiant Organics Limited | May 2022

Q4-FY22/ FY22 HIGHLIGHTS

Valiant Organics Limited | May 2022

QUARTERLY AND ANNUAL FINANCIAL HIGHLIGHTS

Q4-FY22 Consolidated Financial Highlights

FY22 Consolidated Financial Highlights

INR 570 Mn Operating EBITDA

INR 371 Mn Profit After Tax

INR 11.12/ Share EPS

INR 3,476 Mn Operational Revenue

16.40% Operating EBITDA Margin

10.67% PAT Margin

INR 2,049 Mn Operating EBITDA

INR 1,279 Mn Profit After Tax

INR 40.51 / Share EPS

INR 11,533 Mn Operational Revenue

17.77% Operating EBITDA Margin

11.09% PAT Margin

Valiant Organics Limited | May 2022

Q4-FY22/ FY22 Operational Highlights

• Strong Revenue growth in Q4FY22 & Full Year FY22 on a YoY and QoQ basis owing to higher prices as well as volume addition on account of PAP ramp up

• Raw Material prices and market volatility continued to remain under pressure due to the geopolitical situations

• PAP ramp up continues to be on track and we have now achieved production of 300+ MT per month

• OAP & Pharma Intermediates projects both are on-track with no significant delays. OAP Phase 1 trial run has been successful and both OAP and Pharma

Intermediates plant expected to commence production from Q2-FY23

• Direct and deemed exports together accounted for 14% in Q4-FY22 and 16% in FY22

Q4-FY22 Revenue Break-up – Chemistries

FY22 Revenue Break-up – Chemistries

Others, 9%

Ammonolysis, 28%

Chlorination, 27%

Hydrogenation, 36%

Others, 9%

Chlorination, 29%

Ammonolysis, 31%

Hydrogenation, 31%

Valiant Organics Limited | May 2022

Standalone Revenues - Key Chemistries

Chlorination (INR Mn)

Hydrogenation (INR Mn)

Ammonolysis (INR Mn)

Others (INR Mn)

784

599

Q4-FY21

Q4-FY22

2,765

2,131

Y L R E T R A U Q

L A U N N A

900

800

700

600

500

400

300

200

100

3,000

2,500

2,000

1,500

1,000

500

1,048

440

Q4-FY21

Q4-FY22

2,948

1,444

1,200

1,000

800

600

400

200

3,500

3,000

2,500

2,000

1,500

1,000

500

900

800

700

600

500

400

300

200

100

3,500

3,000

2,500

2,000

1,500

1,000

500

824

479

250

184

300

250

200

150

100

Q4-FY21

Q4-FY22

Q4-FY21

Q4-FY22

2,917

1,637

855

530

900

800

700

600

500

400

300

200

100

FY21

FY22

FY21

FY22

FY21

FY22

FY21

FY22

Valiant Organics Limited | May 2022

Volumes – Key Chemistries

Chlorination (MT)

Hydrogenation (MT)

Ammonolysis (MT)

Other (MT)

4,024

4,062

Q4-FY21

Q4-FY22

16,307

12,234

Y L R E T R A U Q

4,500

4,400

4,300

4,200

4,100

4,000

3,900

3,800

3,700

18,000

16,000

14,000

12,000

10,000

8,000

6,000

4,000

2,000

L A U N N A

4,745

4,499

Q4-FY21

Q4-FY22

19,257

14,603

5,000

4,900

4,800

4,700

4,600

4,500

4,400

4,300

4,200

25,000

20,000

15,000

10,000

5,000

3,500

3,450

3,400

3,350

3,300

3,250

3,200

3,150

3,100

3,050

3,000

13,000

12,500

12,000

11,500

11,000

10,500

10,000

9,500

3,137

3,134

3,000

2,500

2,000

1,500

1,000

500

567

366

Q4-FY21

Q4-FY22

Q4-FY21

Q4-FY22

12,745

10,803

2,147

1,486

2,500

2,000

1,500

1,000

500

FY21

FY22

FY21

FY22

FY21

FY22

FY21

FY22

Valiant Organics Limited | May 2022

Quarterly Consolidated Financial Performance

Particulars (INR Mn)

Q4-FY22

Q4-FY21

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/ Diluted EPS (INR)

Valiant Organics Limited | May 2022

3,476

2,906

570

16.40%

491

120

371

10.67%

372

11.12

2,340

1,757

583

24.91%

528

181

347

Y-o-Y

48.5%

65.4%

(2.2)%

Q3-FY22

2,884

2,382

502

(851) Bps

17.41%

46.7%

47.4%

30.8%

(7.0)%

(33.7)%

6.9%

437

115

322

Q-o-Q

20.5%

22.0%

13.5%

(101) Bps

(12.0)%

9.1%

30.8%

12.4%

4.3%

15.2%

14.82%

(415) Bps

11.17%

(50) Bps

(1)

346

9.87

7.5%

12.7%

323

10.70

15.2%

3.9%

Annual Consolidated Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

*FY21 onward figures as per Ind AS

Valiant Organics Limited | May 2022

FY22

11,533

9,484

2,049

17.77%

296

1,762

483

1,279

11.09%

1,285

40.51

FY21*

7,548

5,496

2,052

27.19%

212

1,849

540

1,309

17.34%

1,378

40.97

Y-o-Y

52.8%

72.6%

(0.1)%

(942) Bps

25.4%

39.6%

30.0%

(4.7)%

(10.6)%

(2.3)%

(625) Bps

(91.3)%

(6.7)%

(1.1)%

Quarterly Standalone Financial Performance

Particulars (INR Mn)

Q4-FY22

Q4-FY21

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | May 2022

2,906

2,462

444

15.28%

363

272

9.36%

274

9.72

1702

1,337

365

21.45%

382

106

276

Y-o-Y

70.7%

84.1%

21.6%

(617) Bps

(88.3)%

49.0%

54.5%

(5.0)%

(14.2)%

(1.4)%

Q3-FY22

2,608

2,162

446

17.10%

373

276

Q-o-Q

11.4%

13.9%

(0.4)%

(182) Bps

(43.8)%

(3.9)%

30.8%

(2.7)%

(6.2)%

(1.4)%

16.22%

(686) Bps

10.58%

(122) Bps

(1)

275

9.87

(0.4)%

(1.5)%

277

9.87

(1.1)%

(1.5)%

Annual Standalone Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

*FY21 onward figures as per Ind AS

Valiant Organics Limited | May 2022

FY22

9,484

7,834

1,650

17.40%

273

1,369

340

1,029

10.85%

1,037

36.81

FY21*

5,742

4,170

1,572

27.37%

169

186

1,520

374

1,146

20.00%

1,215

40.98

Y-o-Y

65.2%

87.9%

5.0%

(997) Bps

(66.9)%

46.8%

82.9%

(9.9)%

(9.1)%

(10.2)%

(915) Bps

(88.4)%

(14.7)%

(10.2)%

HISTORICAL FINANCIAL OVERVIEW

Valiant Organics Limited | May 2022

Historical Consolidated Income Statement

Particulars (INR Mn)

Operational Income

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

Profit After Tax(Before merger)

Impact of Scheme of Merger

Profit After Tax (After Merger)

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Diluted EPS (INR per share)

FY19

6,923

5,125

1,798

25.97%

136

1,712

500

1,212

120

1,332

19.24%

1,332

95.29^

FY20

6,749

4,946

1,803

26.71%

158

1,685

423

1,262

18.70%

1,264

44.32

FY21*

7,548

5,496

2,052

27.19%

212

1,849

540

1,309

17.34%

1,378

40.97

FY22*

11,533

9,484

2,049

17.77%

296

1,762

483

1,279

11.09%

1,285

40.51

*FY21 onward figures as per Ind AS FY 2018-19 figures are basis IGAAP accounting standards and hence are not directly comparable with other periods ^ Reduction in EPS is on account of issue of Bonus Shares during FY 2020 - 21. EPS for FY 2019 - 20 is restated accordingly

Valiant Organics Limited | May 2022

Consolidated Balance Sheet

Particulars (INR Mn) EQUITY

a) Equity Share Capital

b) Other Equity

c) Optionally Convertible Preference Shares

d) Non Controlling Interest

LIABILITIES

Non-Current Liabilities

Financial Liabilities

a) Borrowings

b) Lease Liabilities

c) Provisions

d) Deferred Tax Liabilities (Net)

Current Liabilities

a) Financial Liabilities

(i) Borrowings

(ii) Trade Payables

(iii) Other Financial Liabilities

(iv) Lease Liabilities

b) Other Current Liabilities

c) Provisions

FY20 4,007

121

3,736

132

992

841

149

1,692

406

879

359

FY21* 5,086

272

4,747

FY22* 6,489

272

5,856

357

971

1,340

751

203

2,706

1,330

1,072

253

1,058

266

4,018

2,568

1,238

161

GRAND TOTAL - EQUITIES & LIABILITES

6,691

8,763

11,847

*FY21 onward figures as per Ind AS

Valiant Organics Limited | May 2022

Particulars (INR Mn) Non-Current Assets a) Property, Plant and Equipment b) Capital Work In Progress c) Right-Of-Use Assets d) Goodwill e) Goodwill on Consolidation f) Financial Assets (i) Investments (ii) Loans (iii) Other Financial Assets g) Other Non-Current assets Current Assets a) Inventories

b) Financial Assets

(i) Investments (ii) Trade Receivables (iii) Cash and Cash Equivalents (iv) Other Bank balances (v) Loans (vi) Other financial assets

c) Other Current Assets d) Current Tax Assets (Net)

GRAND TOTAL – ASSETS

FY20 4,451 2,729 1,291 7 28 -

181 61 - 154 2,240 449

47 1,326 77 50 7 - 242 42

6,691

FY21* 5,731 4,967 459 6 - 123

23 59 - 94 3,032 722

40 1,568 128 182 5 2 363 22

8,763

FY22* 6,652 5,303 1,116 8 - 123

33 58 - 11 5,195 1,136

46 3,209 251 203 5 3 233 109

11,847

Historical Standalone Income Statement

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT

Tax

Profit After Tax(Before merger)

Impact of scheme of merger

Profit After Tax (After Merger)

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Diluted EPS (INR per share)

FY19

6,060

4,283

1,777

29.32%

118

1,708

496

1,212

120

1,332

21.98%

1,332

95.29

FY20

5,836

4,103

1,733

29.69%

130

1,645

406

1,239

21.23%

1,241

44.32

FY21*

5,742

4,170

1,572

27.37%

169

186

1,520

374

1,146

20.00%

1,215

40.98

FY22*

9,484

7,834

1,650

17.40%

273

1,369

340

1,029 - 1,029

10.85%

1,037

36.81

Valiant Organics Limited | May 2022

Standalone Balance Sheet

Particulars (INR Mn) EQUITY a) Equity Share Capital b) Other Equity

c) Optionally Convertible Preference Shares

LIABILITIES Non-Current Liabilities Financial Liabilities a) Borrowings b) Lease Liabilities c) Provisions d) Deferred Tax Liabilities (Net) e) Other Non-Current Liabilities Current Liabilities a) Financial Liabilities (i) Borrowings (ii) Trade Payables (iii) Other Financial Liabilities (iv) Lease Liabilities b) Other Current Liabilities c) Provisions

d) Current Tax Liabilities (Net)

FY20 3,875 121 3,736

FY21* 5,023 272 4,747

FY22* 6,031 272 5,755

953

962

1,215

808 - 2 143 - 1,462

221 840 355 - 13 33

748 2 15 197 - 2,071

736 1,042 244 3 20 26

940 2 10 263 - 3,583

2,110 1,271 154 2 22 24

Particulars (INR Mn) Non-Current Assets a) Property, Plant and Equipment b) Capital Work In Progress c) Right-Of-Use Assets d) Goodwill (i) Investments in Subsidiaries (ii) Loans (iii) Other Financial Assets j) Other Non-Current assets Current Assets a) Inventories b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash and Cash Equivalents

(iv) Other Bank balances

(v) Loans (vi) Other financial assets c) Other Current Assets

d) Current Tax Assets (Net)

FY20 4,381 2,525 1,291 3 28 145 54 181 154 1,909 409

12 1,108 75

6 - 224

FY21* 5,798 4,771 459 4 - 395 52 24 93 2,258 660

1 1,166 86

5 2 257

FY22* 6,787 5,085 1,102 4 - 501 52 32 11 4,042 973

1 2,532 230

5 3 217

GRAND TOTAL - EQUITIES & LIABILITES

6,290

8,056

10,829

GRAND TOTAL – ASSETS

6,290

8,056

10,829

*FY21 onward figures as per Ind AS

Valiant Organics Limited | May 2022

Consolidated Financial Highlights

Operational Revenue (INR Mn)

EBITDA (INR Mn) & EBITDA Margins (%)

PAT (INR Mn) & PAT Margins (%)

11,533

6,923

6,749

7,548

2,300

2,000

1,700

1,400

1,100

800

500

1,798

1,803

2,052

2,049

25.97%

26.71%

27.19%

17.77%

80.00%

70.00%

60.00%

50.00%

40.00%

30.00%

20.00%

10.00%

0.00%

1,500

1,200

1,332

19.24%

1,309

17.34%

1,279 11.09%

1,282

18.70%

80.00%

70.00%

60.00%

50.00%

40.00%

30.00%

20.00%

10.00%

0.00%

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

Net Debt to Equity (x)

0.49

0.25

0.23

0.30

Net Worth (INR Mn)

6,489

5,086

4,008

3,014

7,000

6,000

5,000

4,000

3,000

2,000

1,000

Return on Capital Employed & Return on Equity (%)

45.98%

44.19%

ROCE

ROE (%)

50.00% 45.00% 40.00% 35.00% 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00%

31.49%

30.41%

33.33%

25.73%

22.39%

19.71%

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

FY19

FY20

FY21

FY22

14,000

12,000

10,000

8,000

6,000

4,000

2,000

0.6

0.5

0.4

0.3

0.2

0.1

0.0

Valiant Organics Limited | May 2022

Capital Market Information

Share Price up to 31st March, 2022

40%

30%

20%

10%

-10%

-20%

-30%

-40%

Apr-21

May-21

Jun-21

Jul-21

Aug-21

Sep-21

Oct-21

Nov-21

Dec-21

Jan-22

Feb-22

Mar-22

Valiant

Sensex

Price Data (As on 31st March, 2022)

Face Value

Market Price

52 Week H/L

Market Cap (Mn)

Equity Shares Outstanding (Mn)

1 Year Avg Trading Volume (‘000)

INR

10.00

920.05

1,845/ 794.7

24,982.57

27.15

84.40

Shareholding pattern (As on 31st March, 2022)

Promoters, 39.00%

Public, 57.35%

FII, 1.73%

DII, 1.31%

AIF, 0.61%

Valiant Organics Limited | May 2022

Disclaimer

Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Valiant Organics Limited (“Company”), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer: Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: valiant@valoremadvisors.com

Valiant Organics Limited | May 2022

THANK YOU

Valiant Organics Limited | April 2022

← All Transcripts VALIANTORG Stock Page →

Valiant Organics Limited has informed the Exchange about Investor Presentation.

Market Movers